Recent Updates
Recently added Catalysts

BMS-986179

Phase 1

Malignant Solid Tumor | Monoclonal antibody | Oncology |Bristol-Myers Squibb Company|Last Updated: Apr 5, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment235

FDA Designations

No designations recorded

Clinical trial landscape

BMS-986179 · 1 trial · 1 indication

Phase 1 1
NCT02754141An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabMalignant Solid Tumor
COMPLETED235 Analytics
PHASE1COMPLETED
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Malignant Solid Tumor
NCT02754141235
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Drug Related AEs, SAEs, AEs Leading to Discontinuation and Deaths.
From first dose to 100 days post last dose: Part 1 up to 25.1 months, Part 2 SC up to 17.5 months, RCC Mono up to 28.1 months, Part 2 up to 27.2 months.

Number of participants with drug related adverse events (AE), drug related serious adverse events (SAE), drug related AEs Leading to discontinuation and drug related deaths

Secondary Endpoints

Number of Participants With a Best Overall Response (BOR) at Week 24
from initial treatment to week 24
Percentage of Participants With an Objective Response Rate (ORR) at Week 24
from initial treatment to week 24
Progression Free Survival Rate (PFSR) at Week 24
from initial treatment to week 24
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A-MonotherapyEXPERIMENTALBMS-986179, dose as specified
Arm B- Combination TherapyEXPERIMENTALBMS-986179 + nivolumab, dose as specified
Arm C-Combination TherapyEXPERIMENTALBMS-986179 + rHuPH20, dose as specified

Interventions

NameTypeDescription
BMS-986179BIOLOGICALSpecified dose on specified days
NivolumabBIOLOGICALSpecified dose on specified days
rHuPH20BIOLOGICALSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites24

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Solid cancers that are advanced or have spread (for which alternative therapies were deemed not effective) * Eastern Cooperative Oncology Group (ECOG) 0-1 * ...

Countries:United StatesAustraliaCanadaFranceGermanyItalyNetherlands
Unlock Eligibility Criteria

Frequently asked questions about BMS-986179

What is BMS-986179 used for?

BMS-986179 is an investigational monoclonal antibody being studied for the treatment of malignant solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under investigation for safety and efficacy.

What does BMS-986179 target?

BMS-986179 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. As an immuno-therapy, it is being studied to understand its mechanism of action in treating malignant solid tumors, though the exact target is not publicly detailed.

Who makes BMS-986179?

BMS-986179 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate this investigational drug for oncology indications.

What phase is BMS-986179 in?

BMS-986179 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains under clinical investigation for malignant solid tumors.

What clinical trials is BMS-986179 in?

BMS-986179 has been studied in one completed Phase 1 clinical trial with the identifier NCT02754141. This trial evaluated BMS-986179 given alone and in combination with nivolumab in 235 participants with malignant solid tumors across multiple countries, including the United States, Australia, Canada, France, Germany, Italy, and the Netherlands.

Is BMS-986179 the same as nivolumab?

No, BMS-986179 is not the same as nivolumab. BMS-986179 is an investigational monoclonal antibody being studied alone and in combination with nivolumab in a Phase 1 clinical trial. Nivolumab is a separate, approved immunotherapy drug, while BMS-986179 is still in clinical development.